Immortalized Cell Line Market Research Report - Global Forecast till 2030

Immortalized Cell Line Market Research Report Information by Method (Virus Induction, HTERT Expression, Inactivation of Tumor Suppression Genes and others), Application (Diagnostics, Drug Discovery, Vaccine Production, Tissue Engineering and Regenerative Medicines and others), End User (Pharmaceutical and Biopharmaceutical Companies, Contract Research Organizations and Research Laboratories) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2030

ID: MRFR/LS/0267-CR | 130 Pages | Author: Rahul Gotadki | August 2019         

Immortalized Cell Line Market Speak to Analyst Request a Free Sample


Global Immortalized Cell Line Market Overview


The Immortalized Cell Line Market is expected to reach USD 2601.83 Million by 2030 at 4.90% CAGR during the forecast period 2022-2030  Immortalized cell lines are either tumorous cells that do not stop dividing or cells that have been artificially manipulated to proliferate indefinitely and can, thus, be cultured over several generations. These cell lines are expected to grow due to the rise in vaccine production and innovative technologies.

Besides, the ability of cell line culture to provide more physiologically relevant information and more accurate data in-vitro tests has led cell line culture systems to become acceptable in comparison to media culture.

The increasing application in biotech and pharmaceutical companies and hospitals, a growing number of patients in need of organ transplantation, and the rise in the patient population affected by cancer are the major drivers propelling market growth. However, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination may hinder the growth of the market.

Immortalized Cell Line Market

Immortalized Cell Line Market Trends


The increasing demand for organ donation due to scarcity in the availability of organs is driving the need for artificially created biological cells. For instance, according to the US Department of Health & Human Services Organ Procurement and Transplantation Network (OPTN), as of November 2016, 121,678 patients were waiting for a life-saving organ transplant. This rising demand for an organ transplant is expected to drive the growth of the market during the forecast period. Additionally, increasing application in biotech and pharmaceutical companies and hospitals and rise in the patient population affected by cancer are likely to support market growth. On the other hand, the high cost of equipment and developing a stable strain of cell line and maintaining and preventing it from contamination is anticipated to hamper the market growth.

Immortalized Cell Line Market Size, by End User, 2017 (USD Million)  Immortalized Cell Line Market


Source: MRFR Analysis

Immortalized Cell Line Market Segment Insights


The immortalized cell line market has been segmented into method, application, and end user. 

Based on the method, the global market has been segmented into virus induction, hTERT expression, inactivation of tumor suppression genes, and others. The virus induction segment is further divided into EBV genes, SV40 T antigen, HPV-16 E6/6 gene, and others. The hTERT expression segment is sub-segmented into P53 and Myc T58A.

The immortalized cell line market, based on application, is segmented into diagnostics, drug discovery, vaccine production, tissue engineering and regenerative medicine, and others.

Based on end user, the global market is segmented into pharmaceutical and biopharmaceutical companies, Contract Research Organizations (CROs), and research laboratories. The pharmaceutical and biopharmaceutical companies segment accounted for a market value of USD 1,323.79 million in 2017.  

 

Immortalized Cell Line Market Key Players

The prominent players in the immortalized cell line market are 



  • Thermo Fisher Scientific (US)

  • ATCC (American Type Culture Collection Inc.) (US)

  • Valneva (France), 

  • Sartorius AG (Germany)

  • Lonza Group, AG (Switzerland)

  • Merck KGaA (Germany)

  • Selexis SA (Switzerland)

  • WuXi App Tec (China)

  • European Collection of Authenticated Cell Cultures (ECACC) (Europe)

  • Corning Incorporated (US)



Some of the key strategies followed by the players operating in the immortalized cell line market are innovation, product development, acquisition, and expansion.

Immortalized Clinell Line Market Share, by Region, 2017 (%)

Immortalized Cell Line Market


 Source: MRFR Analysis


Immortalized Clinell Line Market Regional Insights


The immortalized cell e market, based on region, is segmented into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

The Americas is estimated to dominate the immortalized cell line market during the forecast period. This is attributed to an increase in the occurrence of cancer, the presence of well-established pharmaceutical and biotechnology industry, increasing awareness of immortalized cell lines, and strong research funding.

The European market for immortalized cell line is expected to be the second-largest during the forecast period. Increasing government support, well-developed technology, and rising cases of cancer are expected to boost the growth of the market in this region.    

Asia-Pacific is estimated to be the fastest-growing market due to the increasing expenditure on healthcare by government and private sector companies. Moreover, the growing awareness about healthcare and large untapped patient population have led to the increased focus of key players on expansion in this region. Furthermore, the region accounted for a market share of 17.8% in 2017.

The immortalized cell line market in the Middle East & Africa is expected to hold the least market share.


Immortalized Cell Line Industry Developments



In January 2024,Thermo Fisher Scientific Launched new Gibco™ Advanced DMEM/F12 media optimized for immortalized cell lines, claiming improved growth and performance.


In September2023,Lonza Group AG Announced partnership with CStone Pharmaceuticals to optimize and manufacture immortalized cell lines for CAR-T cell therapy development.


Immortalized Cell Line Market Segmentation


Immortalized Cell Line Method Outlook




  • Virus Induction

  • EBV genes

  • SV40 T antigen

  • HPV-16 E6/6 gene

  • Others 

  • HTERT Expression

  • P53

  • Myc T58A

  • Inactivation of Tumour Suppression Genes

  • Others



Immortalized Cell Line Application Outlook


  • Diagnostics

  • Drug Discovery

  • Vaccine Production

  • Tissue Engineering and Regenerative Medicines

  • Others



Immortalized Cell Line End User Outlook




  • Pharmaceutical and Biopharmaceutical Companies

  • Contract Research Organizations

  • Research Laboratories



Immortalized Cell Line Regional Outlook






  • Americas





    • North America





      • US




      • Canada





    • South America







  • Europe





    • Western Europe





      • Germany




      • UK




      • France




      • Italy




      • Spain




      • Rest of Western Europe





    • Eastern Europe







  • Asia-Pacific





    • China




    • Japan




    • India




    • South Korea




    • Rest of Asia-Pacific







  • Middle East & Africa





    • Middle East




    • Africa







Intended Audience





  • Research and development (R&D) companies




  • Government research institutes




  • Academic institutes and universities




Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 2601.83 Million
  CAGR   4.90% (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Method, Application, End User and Region
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors  Virus Induction, EBV genes, SV40 T antigen, HPV-16 E6/6 gene, HTERT Expression, Myc T58A, Inactivation of Tumour Suppression Genes
  Key Market Opportunities   Increasing demand for organ donation due to scarcity in the availability of organs
  Key Market Drivers   Increasing government support, well-developed technology




Frequently Asked Questions (FAQ) :

Immortalized Cell Line Market is predicted to touch USD 2601.83 Million by 2030.

Immortalized Cell Line Market is projected to grow at a 4.90% CAGR between 2022-2030.

North America is projected to dominate the Immortalized Cell Line Market.

Pharmaceutical & biopharmaceutical companies will dominate the Immortalized Cell Line Market.

Increasing prevalence of cancer, growing need for organ transplantation, and rising application in hospitals, pharmaceutical & biotech companies are boosting market growth.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid